SUO-CTC & Syncromune SUO 2025 Investigator Meeting

Friday, December 5, 2:20pm - 3:20pm (EST)

Description: Syncromune Chief Medical Officer, Urology, and LEGION-100 Phase 2 trial proctor, Dr. Andriole, will provide in-depth insights into SYNC-T SV-102, a novel third-generation combination intratumoral/locoregional immunotherapy designed to elicit a systemic antitumor response in patients with metastatic castration-resistant prostate cancer (mCRPC).

This session will showcase Phase 1 clinical results demonstrating safety, immune activation, and early signs of efficacy, highlighting how SYNC-T SV-102 is reshaping the therapeutic landscape for advanced prostate cancer.

The symposium will also spotlight the LEGION-100 Phase 2 clinical trial, now actively enrolling patients and recruiting clinical trial sites across the U.S. Dr. Andriole will share insights into the trial’s design, scientific rationale, and the opportunity for institutions to partner in evaluating this cutting-edge immunotherapy.

Speaker: Gerald Andriole, M.D., Chief Medical Officer, Urology, Syncromune, Inc.

Time shown in -04:00 America, New York

Link:

Friday, December 5, 2:20pm - 3:20pm (EST)

Please fill out the information below to register for the event.

Goingdone
Maybequestion_mark
Can't Goclear

Name

Institution / Clinic

Confirmed

A confirmation email is on its way. Check your spam folder if it doesn't show up.

Add to Calendar 2025/12/05 14:20:00 2025/12/05 15:20:00 America/New_York SUO-CTC & Syncromune SUO 2025 Investigator Meeting 340 N 3rd St
Phoenix, AZ 85004

---

Description: Syncromune Chief Medical Officer, Urology, and LEGION-100 Phase 2 trial proctor, Dr. Andriole, will provide in-depth insights into SYNC-T SV-102, a novel third-generation combination intratumoral/locoregional immunotherapy designed to elicit a systemic antitumor response in patients with metastatic castration-resistant prostate cancer (mCRPC).

This session will showcase Phase 1 clinical results demonstrating safety, immune activation, and early signs of efficacy, highlighting how SYNC-T SV-102 is reshaping the therapeutic landscape for advanced prostate cancer.

The symposium will also spotlight the LEGION-100 Phase 2 clinical trial, now actively enrolling patients and recruiting clinical trial sites across the U.S. Dr. Andriole will share insights into the trial’s design, scientific rationale, and the opportunity for institutions to partner in evaluating this cutting-edge immunotherapy.

Speaker: Gerald Andriole, M.D., Chief Medical Officer, Urology, Syncromune, Inc. Sheraton Phoenix Downtown, Ahwatukee A Room SUO-CTC & Syncromune, Inc. false 30

Response submitted

A confirmation email is on its way. Check your spam folder if it doesn't show up.

Response submitted

Thanks for letting us know.

Limited seats left

Sheraton Phoenix Downtown, Ahwatukee A Room

SUO-CTC & Syncromune, Inc.